Search

Your search keyword '"Sbianchi, Giulia"' showing total 19 results
Start Over Author "Sbianchi, Giulia" Publication Year Range Last 10 years
19 results on '"Sbianchi, Giulia"'

1. Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP

Author

Onida, Francesco, Sbianchi, Giulia, Radujkovic, Aleksandar, Sockel, Katja, Kröger, Nicolaus, Sierra, Jorge, Socié, Gerard, Cornelissen, Jan, Poiré, Xavier, Raida, Luděk, Bourhis, Jean Henri, Finke, Jürgen, Passweg, Jakob, Salmenniemi, Urpu, Schouten, Harry C., Beguin, Yves, Martin, Sonja, Deconinck, Eric, Ganser, Arnold, Zver, Samo, Lioure, Bruno, Rohini, Radia, Koster, Linda, Hayden, Patrick, Iacobelli, Simona, Robin, Marie, and Yakoub-Agha, Ibrahim

Published
2022
Full Text
View/download PDF

3. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Author

Kröger, Nicolaus, Sbianchi, Giulia, Sirait, Tiarlan, Wolschke, Christine, Beelen, Dietrich, Passweg, Jakob, Robin, Marie, Vrhovac, Radovan, Helbig, Grzegorz, Sockel, Katja, Conneally, Eibhlin, Rubio, Marie Thérèse, Beguin, Yves, Finke, Jürgen, Bernasconi, Paolo, Morozova, Elena, Clausen, Johannes, von dem Borne, Peter, Schaap, Nicolaas, Schroyens, Wilfried, Patriarca, Francesca, Di Renzo, Nicola, Yeğin, Zeynep Arzu, Hayden, Patrick, McLornan, Donal, and Yakoub-Agha, Ibrahim

Published
2021
Full Text
View/download PDF

4. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents

Author

Sahebi, Firoozeh, Iacobelli, Simona, Sbianchi, Giulia, Koster, Linda, Blaise, Didier, Reményi, Péter, Russell, Nigel H., Ljungman, Per, Kobbe, Guido, Apperley, Jane, Trneny, Marek, Krejci, Marta, Wiktor-Jedrzejczak, Wieslaw, Sanchez, James F., Schaap, Nicolaas, Isaksson, Cecilia, Lenhoff, Stig, Browne, Paul, Scheid, Christof, Wilson, Keith M.O., Yakoub-Agha, Ibrahim, Muñiz, Soledad González, Schönland, Stefan, Morris, Curly, Garderet, Laurent, and Kröger, Nicolaus

Published
2018
Full Text
View/download PDF

5. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT

Author

Kröger, Nicolaus, Sbianchi, Giulia, Sirait, Tiarlan, Wolschke, Christine, Beelen, Dietrich, Passweg, Jakob, Robin, Marie, Vrhovac, Radovan, Helbig, Grzegorz, Sockel, Katja, Conneally, Eibhlin, Rubio, Marie Thérèse, Beguin, Yves, Finke, Jürgen, Bernasconi, Paolo, Morozova, Elena, Clausen, Johannes, von dem Borne, Peter, Schaap, Nicolaas, Schroyens, Wilfried, Patriarca, Francesca, Di Renzo, Nicola, Yeğin, Zeynep Arzu, Hayden, Patrick, McLornan, Donal, and Yakoub-Agha, Ibrahim

Abstract

JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n= 274) or with (n= 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p= 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p= 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p= 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p= 0.03) and HLA mismatch donor (p= 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome.

Published
2024
Full Text
View/download PDF

6. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study

Author

Waszczuk-Gajda, Anna, primary, Penack, Olaf, additional, Sbianchi, Giulia, additional, Koster, Linda, additional, Blaise, Didier, additional, Reményi, Péter, additional, Russell, Nigel, additional, Ljungman, Per, additional, Trneny, Marek, additional, Mayer, Jiri, additional, Iacobelli, Simona, additional, Kobbe, Guido, additional, Scheid, Christof, additional, Apperley, Jane, additional, Touzeau, Cyrille, additional, Lenhoff, Stig, additional, Jantunen, Esa, additional, Anagnostopoulos, Achilles, additional, Paris, Laura, additional, Browne, Paul, additional, Thieblemont, Catherine, additional, Schaap, Nicolaas, additional, Sierra, Jorge, additional, Yakoub-Agha, Ibrahim, additional, Garderet, Laurent, additional, Styczynski, Jan, additional, Schoemans, Helene, additional, Moiseev, Ivan, additional, Duarte, Rafael F., additional, Peric, Zinaida, additional, Montoto, Silvia, additional, van Biezen, Anja, additional, Mikulska, Malgorzata, additional, Aljurf, Mahmoud, additional, Ruutu, Tapani, additional, Kröger, Nicolaus, additional, Morris, Curly, additional, Koenecke, Christian, additional, Schoenland, Stefan, additional, and Basak, Grzegorz W., additional

Published
2022
Full Text
View/download PDF

7. Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.

Author

Chalandon, Yves, Sbianchi, Giulia, Gras, Luuk, Koster, Linda, Apperley, Jane, Byrne, Jenny, Salmenniemi, Urpu, Sengeloev, Henrik, Aljurf, Mahmoud, Helbig, Grzegorz, Kinsella, Francesca, Choi, Goda, Reményi, Péter, Snowden, John A., Robin, Marie, Lenhoff, Stig, Mielke, Stephan, Passweg, Jakob, Broers, Annoek E. C., and Kröger, Nicolaus

Published
2023
Full Text
View/download PDF

8. IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study

Author

Lawless, Sarah, primary, Sbianchi, Giulia, additional, Morris, Curly, additional, Iacobelli, Simona, additional, Bosman, Paul, additional, Blaise, Didier, additional, Reményi, Péter, additional, Byrne, J.L., additional, Mayer, Jiri, additional, Apperley, Jane, additional, Lund, Johan, additional, Kobbe, Guido, additional, Schaap, Nicolaas, additional, Isaksson, Cecilia, additional, Lenhoff, Stig, additional, Basak, Grzegorz, additional, Touzeau, Cyrille, additional, Wilson, Keith M.O., additional, González Muñiz, Soledad, additional, Scheid, Christof, additional, Browne, Paul, additional, Anagnostopoulos, Achilles, additional, Rambaldi, Alessandro, additional, Jantunen, Esa, additional, Kröger, Nicolaus, additional, Schönland, Stefan, additional, Yakoub-Agha, Ibrahim, additional, and Garderet, Laurent, additional

Published
2021
Full Text
View/download PDF

9. Impact of Prior Jak-Inhibitor Therapy With Ruxolitinib on Outcome After Allogeneic Stem Cell Transplantation For Myelofibrosis. A Large EBMT-CMWP Study

Author

Kroeger, Nicolaus, Sbianchi, Giulia, Sirait, Tiarlan, Beelen, Dietrich, Passweg, Jakob, Robin, Marie, Vrhovac, Radovan, Helbig, Grzegor, Sockel, Katja, Conneally, Eibhlin, Rubio, Marie Therese, Beguin, Yves, Finke, Juergen, Bernasconi, Paolo, Morozova, Elena, Clausen, Johannes, Dem Borne, Peter, Nicolaas Schaap, Schroyens, Wilfried, Patriarca, Francesca, Di Renzo, Nicola, Yegin, Zeynep Arzu, Hayden, Patrick, Mclornan, Donal, and Yakoub-Agha, Ibrahim

Published
2021

10. Prognostic impact of early‐versus‐late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT

Author

Garderet, Laurent, primary, Sbianchi, Giulia, additional, Iacobelli, Simona, additional, Blaise, Didier, additional, Byrne, Jenny L., additional, Remenyi, Peter, additional, Apperley, Jane F., additional, Touzeau, Cyrille, additional, Isaksson, Cecilia, additional, Browne, Paul, additional, Mayer, Jiri, additional, Lenhoff, Stig, additional, Gonzalez Muniz, Soledad, additional, Parody Porras, Rocio, additional, Basak, Grzegorz, additional, Poire, Xavier, additional, Trneny, Marek, additional, Nagler, Arnon, additional, Michieli, Mariagrazia, additional, Tanase, Alina, additional, Koster, Linda, additional, Hayden, Patrick J., additional, Beksac, Meral, additional, Schönland, Stefan, additional, and Yakoub‐Agha, Ibrahim, additional

Published
2021
Full Text
View/download PDF

11. Melphalan 140 mg/m(2) or 200 mg/m(2) for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Author

Auner, Holger W., Iacobelli, S., Sbianchi, Giulia, Knol-Bout, Cora, Blaise, D., Russell, Nigel H., Schaap, N.P.M., Garderet, L., and Kroeger, Nicolaus

Subjects
All institutes and research themes of the Radboud University Medical Center, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Contains fulltext : 190028.pdf (Publisher’s version ) (Open Access)

Published
2018

12. Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party

Author

Onida, Francesco, primary, Sbianchi, Giulia, additional, Koster, Linda, additional, Iacobelli, Simona, additional, Dreger, Peter, additional, Bornhäuser, Martin, additional, Kröger, Nicolaus, additional, Sierra, Jorge, additional, Socié, Gérard, additional, Cornelissen, Jan J, additional, Poire, Xavier, additional, Faber, Edgar, additional, Bourhis, Jean-Henri, additional, Finke, Jürgen, additional, Passweg, Jakob R., additional, Salmenniemi, Urpu, additional, Schouten, Harry C., additional, Beguin, Yves, additional, Martin, Sonja, additional, Deconinck, Eric, additional, Ganser, Arnold, additional, Zver, Samo, additional, Lioure, Bruno, additional, Russell, Nigel H., additional, Robin, Marie, additional, and Yakoub-Agha, Ibrahim, additional

Published
2018
Full Text
View/download PDF

13. Outcomes after Unrelated Cord Blood Transplantation (UCBT) in Patients with Chronic Myeloid Leukemia (CML): A Retrospective Study from the Cmwp-EBMT

Author

De Lavallade, Hugues, primary, Sbianchi, Giulia, additional, Koster, Linda, additional, Sanz, Jaime, additional, Angelucci, Emanuele, additional, Socie, Gerard, additional, Pietri, Isabelle, additional, Labussière-Wallet, Hélène, additional, Cornelissen, Jan J, additional, Gedde-Dahl, Tobias, additional, Petersen, Eefke J., additional, Bonifazi, Francesca, additional, Sierra, Jorge, additional, Carre, Martin, additional, Marchand, Tony, additional, Pochon, Cecile, additional, Russel, Nigel H, additional, Potter, Victoria, additional, Sengeloev, Henrik, additional, Ljungman, Per, additional, Lapusan, Simona, additional, Blaise, Didier, additional, Iori, Anna Paola, additional, Ruggeri, Annalisa, additional, Chalandon, Yves, additional, and Yakoub-Agha, Ibrahim, additional

Published
2018
Full Text
View/download PDF

15. Melphalan 140 mg/m 2 or 200 mg/m 2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Author

Auner, Holger W., primary, Iacobelli, Simona, additional, Sbianchi, Giulia, additional, Knol-Bout, Cora, additional, Blaise, Didier, additional, Russell, Nigel H., additional, Apperley, Jane F., additional, Pohlreich, David, additional, Browne, Paul V., additional, Kobbe, Guido, additional, Isaksson, Cecilia, additional, Lenhoff, Stig, additional, Scheid, Christof, additional, Touzeau, Cyrille, additional, Jantunen, Esa, additional, Anagnostopoulos, Achilles, additional, Yakoub-Agha, Ibrahim, additional, Tanase, Alina, additional, Schaap, Nicolaas, additional, Wiktor-Jedrzejczak, Wieslaw, additional, Krejci, Marta, additional, Schönland, Stefan O., additional, Morris, Curly, additional, Garderet, Laurent, additional, and Kröger, Nicolaus, additional

Published
2017
Full Text
View/download PDF

16. Impact of T‐cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.

Author

Samarasinghe, Sujith, Clesham, Katherine, Iacobelli, Simona, Sbianchi, Giulia, Knol, Cora, Hamladji, Rose‐Marie, Socié, Gerard, Aljurf, Mahmoud, Koh, Mickey, Sengeloev, Henrik, Dalle, Jean‐Hugues, Robinson, Stephen, Van Lint, Maria Teresa, Halkes, Constantijn J. M., Beelen, Dietrich, Mufti, Ghulam J., Snowden, John, Blaise, Didier, de Latour, Regis Peffault, and Marsh, Judith

Published
2019
Full Text
View/download PDF

17. Second Autologous Stem Cell Transplantation in Poor Stem Cell Mobilizers Multiple Myeloma Patients

Author

Sever, Matjaz, Sbianchi, Giulia, Iacobelli, Simona, van der Werf, Steffie, Wieslaw, Wiktor-Jedrzejczak, Blaise, Didier, Apperley, Jane F., Mohty, Mohamad, Scheid, Christof, Wilson, Keith, Russel, Nigel H, Kalhs, Peter, Chevallier, Patrice, Ringhoffer, Mark, Kobbe, Guido, Mayer, Jiri, Jost, Edgar, Zudaire, Teresa, Schiel, Xaver, Isaksson, Cecilia, Trneny, Marek, Schönland, Stefan, Morris, Curly, Garderet, Laurent, and Kroeger, Nicolaus

Published
2017
Full Text
View/download PDF

18. Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party

Author

Samarasinghe, S, Clesham, K, Iacobelli, S, Sbianchi, G, Knol, C, Hamladji, R-M, Socié, G, Aljurf, M, Koh, M, Sengeloev, H, Dalle, J-H, Robinson, S, Van Lint, MT, Halkes, CJ, Beelen, D, Mufti, GJ, Snowden, J, Blaise, D, Peffault de Latour, R, Marsh, J, Dufour, C, Risitano, AM, Severe Aplastic Anaemia Working Party of the EBMT, Samarasinghe, Sujith, Clesham, Katherine, Iacobelli, Simona, Sbianchi, Giulia, Knol, Cora, Hamladji, Rose-Marie, Socié, Gerard, Aljurf, Mahmoud, Koh, Mickey, Sengeloev, Henrik, Dalle, Jean-Hugue, Robinson, Stephen, Van Lint, Maria Teresa, Halkes, Constantijn J. M., Beelen, Dietrich, Mufti, Ghulam J., Snowden, John, Blaise, Didier, de Latour, Regis Peffault, Marsh, Judith, Dufour, Carlo, and Risitano, Antonio M

Subjects
Adult, Male, medicine.medical_specialty, Transplantation Conditioning, Adolescent, Anemia, T-Lymphocytes, medicine.medical_treatment, Medizin, Graft vs Host Disease, Hematopoietic stem cell transplantation, Lower risk, Gastroenterology, Lymphocyte Depletion, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Living Donors, medicine, Humans, Young adult, Child, Alemtuzumab, Aged, Antilymphocyte Serum, Retrospective Studies, Transplant Conditioning, business.industry, Hematopoietic Stem Cell Transplantation, Immunization, Passive, Anemia, Aplastic, Infant, Hematology, Middle Aged, Settore MED/15, medicine.disease, Transplantation, Settore MED/01, Treatment Outcome, surgical procedures, operative, Child, Preschool, 030220 oncology & carcinogenesis, Female, business, 030215 immunology, medicine.drug
Abstract

We retrospectively analyzed the outcomes of 1837 adults and children with severe aplastic anemia (SAA) who underwent matched sibling donor (MSD) and matched unrelated donor (MUD) hemopoietic stem cell transplantation (HSCT) between 2000 and 2013. Patients were grouped by transplant conditioning containing either anti‐thymocyte globulin (ATG) (n = 1283), alemtuzumab (n = 261), or no serotherapy (NS) (n = 293). The risks of chronic GvHD were significantly reduced when ATG or alemtuzumab were compared with NS (P = .021 and .003, respectively). Acute GVHD was significantly reduced in favor of alemtuzumab compared with ATG (P = .012) and NS (P < .001). By multivariate analysis, when compared with ATG, alemtuzumab was associated with a lower risk of developing acute (OR 0.262; 95% CI 0.14‐0.47; P < .001) and chronic GVHD (HR 0.58; 95% CI 0.35‐0.94; P = .027). OS was significantly better in ATG and alemtuzumab patients compared with NS (P = .010 and .025). Our data shows inclusion of serotherapy in MSD and MUD HSCT for patients with SAA reduces chronic GVHD and provides a survival advantage over patients not receiving serotherapy. Notably, alemtuzumab reduced the risk of acute and chronic GvHD compared with ATG and indicates that alemtuzumab might be the serotherapy of choice for MSD and MUD transplants for SAA.

Published
2018

19. Melphalan 140 mg/m 2 or 200 mg/m 2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party.

Author

Auner HW, Iacobelli S, Sbianchi G, Knol-Bout C, Blaise D, Russell NH, Apperley JF, Pohlreich D, Browne PV, Kobbe G, Isaksson C, Lenhoff S, Scheid C, Touzeau C, Jantunen E, Anagnostopoulos A, Yakoub-Agha I, Tanase A, Schaap N, Wiktor-Jedrzejczak W, Krejci M, Schönland SO, Morris C, Garderet L, and Kröger N

Subjects
Adult, Aged, Dose-Response Relationship, Drug, Female, Hematopoietic Stem Cell Transplantation methods, Humans, Male, Melphalan therapeutic use, Middle Aged, Recurrence, Survival Analysis, Transplantation Conditioning methods, Transplantation, Autologous methods, Treatment Outcome, Melphalan administration & dosage, Multiple Myeloma therapy
Abstract

Melphalan at a dose of 200 mg/m 2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m 2 is often used in clinical practice in patients perceived to be at risk of excess toxicity. To determine whether melphalan 200 mg/m 2 and melphalan 140 mg/m 2 are equally effective and tolerable in clinically relevant patient subgroups we analyzed 1964 first single autologous transplantation episodes using a series of Cox proportional-hazards models. Overall survival, progression-free survival, cumulative incidence of relapse, non-relapse mortality, hematopoietic recovery and second primary malignancy rates were not significantly different between the melphalan 140 mg/m 2 (n=245) and melphalan 200 mg/m 2 (n=1719) groups. Multivariable subgroup analysis showed that disease status at transplantation interacted with overall survival, progression-free survival, and cumulative incidence of relapse, with a significant advantage associated with melphalan 200 mg/m 2 in patients transplanted in less than partial response (adjusted hazard ratios for melphalan 200 mg/m 2 versus melphalan 140 mg/m 2 : 0.5, 0.54, and 0.56). In contrast, transplantation in very good partial or complete response significantly favored melphalan 140 mg/m 2 for overall survival (adjusted hazard ratio: 2.02). Age, renal function, prior proteasome inhibitor treatment, gender, or Karnofsky score did not interact with overall/progression-free survival or relapse rate in the melphalan dose groups. There were no significant survival or relapse rate differences between melphalan 200 mg/m 2 and melphalan 140 mg/m 2 patients with high-risk or standard-risk chromosomal abnormalities. In conclusion, remission status at the time of transplantation may favor the use of melphalan 200 mg/m 2 or melphalan 140 mg/m 2 for key transplant outcomes (NCT01362972)., (Copyright© 2018 Ferrata Storti Foundation.)

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results